Viral strategies to modulate NKG2D-ligand expression in Human Cytomegalovirus infection

New Horizons in Translational Medicine

Volumn 2, Issue 6-7, 2015, Pages 159-166

  Reyburn, Hugh ^a   Esteso, Gloria ^a   Ashiru, Omodele ^b   Vales Gomez, Mar ^a  

^a CSIC   (Spain)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Human cytomegalovirus (HCMV); Immune evasion; MICA; Natural Killer cells; NKG2D; UL142; UL16; ULBP

Indexed keywords

DISINTEGRIN; METALLOPROTEINASE; NATURAL KILLER CELL RECEPTOR NKG2D; UL142 GLYCOPROTEIN; UL16 GLYCOPROTEIN; UNCLASSIFIED DRUG; US18 GLYCOPROTEIN; US20 GLYCOPROTEIN; US9 GLYCOPROTEIN; VIRUS GLYCOPROTEIN; WHEAT GERM AGGLUTININ;

CD8+ T LYMPHOCYTE; CYTOMEGALOVIRUS INFECTION; GENE EXPRESSION REGULATION; HUMAN; IMMUNE EVASION; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; VIRUS GENE;

EID: 84956636912     PISSN: None     EISSN: 23075023     Source Type: Journal    
DOI: 10.1016/j.nhtm.2015.11.002     Document Type: Review

References (85)

1. Amano Y., Yamashita Y., Kojima K., Yoshino K., Tanaka N., Sugamura K., Takeshita T. Hrs recognizes a hydrophobic amino acid cluster in cytokine receptors during ubiquitin-independent endosomal sorting. J. Biol. Chem. 2011, 286:15458-15472.
2. Antoun A., Jobson S., Cook M., O'Callaghan C.A., Moss P., Briggs D.C. Single nucleotide polymorphism analysis of the NKG2D ligand cluster on the long arm of chromosome 6: Extensive polymorphisms and evidence of diversity between human populations. Hum. Immunol. 2010, 71:610-620.
3. Ashiru O., Bennett N.J., Boyle L.H., Thomas M., Trowsdale J., Wills M.R. NKG2D ligand MICA is retained in the cis-Golgi apparatus by human cytomegalovirus protein UL142. J. Virol. 2009, 83:12345-12354.
4. Ashiru O., Lopez-Cobo S., Fernandez-Messina L., Pontes-Quero S., Pandolfi R., Reyburn H.T., Vales-Gomez M. A GPI anchor explains the unique biological features of the common NKG2D-ligand allele MICA*008. Biochem. J. 2013, 454:295-302.
5. Bahram S., Bresnahan M., Geraghty D.E., Spies T. A second lineage of mammalian major histocompatibility complex class I genes. Proc. Natl. Acad. Sci. S. A 1994, 91:6259-6263.
6. Baker A.H., Edwards D.R., Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J. Cell. Sci. 2002, 115:3719-3727.
7. Bauer S., Groh V., Wu J., Steinle A., Phillips J.H., Lanier L.L., Spies T. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999, 285:727-729.
8. Bennett N.J., Ashiru O., Morgan F.J., Pang Y., Okecha G., Eagle R.A., Trowsdale J., Sissons J.G., Wills M.R. Intracellular sequestration of the NKG2D ligand ULBP3 by human cytomegalovirus. J. Immunol. 2010, 185:1093-1102.
9. Boutet P., Aguera-Gonzalez S., Atkinson S., Pennington C.J., Edwards D.R., Murphy G., Reyburn H.T., Vales-Gomez M. Cutting edge: the metalloproteinase ADAM17/TNF-alpha-converting enzyme regulates proteolytic shedding of the MHC class I-related chain B protein. J. Immunol. 2009, 182:49-53.
10. Brew K., Dinakarpandian D., Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim. Biophys. Acta 2000, 1477:267-283.
11. Butler J.E., Moore M.B., Presnell S.R., Chan H.W., Chalupny N.J., Lutz C.T. Proteasome regulation of ULBP1 transcription. J. Immunol. 2009, 182:6600-6609.
12. Cai Q., Sheng Z.H. Uncovering the role of Snapin in regulating autophagy-lysosomal function. Autophagy 2011, 7:445-447.
13. Cha T.A., Tom E., Kemble G.W., Duke G.M., Mocarski E.S., Spaete R.R. Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. J. Virol. 1996, 70:78-83.
14. Chalupny N.J., Rein-Weston A., Dosch S., Cosman D. Down-regulation of the NKG2D ligand MICA by the human cytomegalovirus glycoprotein UL142. Biochem. Biophys. Res. Commun. 2006, 346:175-181.
15. Cosman D., Mullberg J., Sutherland C.L., Chin W., Armitage R., Fanslow W., Kubin M., Chalupny N.J. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001, 14:123-133.
16. Das S., Skomorovska-Prokvolit Y., Wang F.Z., Pellett P.E. Infection-dependent nuclear localization of US17, a member of the US12 family of human cytomegalovirus-encoded seven-transmembrane proteins. J. Virol. 2006, 80:1191-1203.
17. Das S., Vasanji A., Pellett P.E. Three-dimensional structure of the human cytomegalovirus cytoplasmic virion assembly complex includes a reoriented secretory apparatus. J. Virol. 2007, 81:11861-11869.
18. Davison A.J., Dolan A., Akter P., Addison C., Dargan D.J., Alcendor D.J., McGeoch D.J., Hayward G.S. The human cytomegalovirus genome revisited: comparison with the chimpanzee cytomegalovirus genome. J. Gen. Virol. 2003, 84:17-28.
19. Dunn C., Chalupny N.J., Sutherland C.L., Dosch S., Sivakumar P.V., Johnson D.C., Cosman D. Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity. J. Exp. Med. 2003, 197:1427-1439.
20. Dunn W., Chou C., Li H., Hai R., Patterson D., Stolc V., Zhu H., Liu F. Functional profiling of a human cytomegalovirus genome. Proc. Natl. Acad. Sci. USA 2003, 100:14223-14228.
21. Esteso G., Luzon E., Sarmiento E., Gomez-Caro R., Steinle A., Murphy G., Carbone J., Vales-Gomez M., Reyburn H.T. Altered microRNA expression after infection with human cytomegalovirus leads to TIMP3 downregulation and increased shedding of metalloprotease substrates, including MICA. J. Immunol. 2014, 193:1344-1352.
22. Fernandez-Messina L., Reyburn H.T., Vales-Gomez M. Human NKG2D-ligands: cell biology strategies to ensure immune recognition. Front. Immunol. 2012, 3:299.
23. Fielding C.A., Aicheler R., Stanton R.J., Wang E.C., Han S., Seirafian S., Davies J., McSharry B.P., Weekes M.P., Antrobus P.R., Prod'homme V., Blanchet F.P., Sugrue D., Cuff S., Roberts D., Davison A.J., Lehner P.J., Wilkinson G.W., Tomasec P. Two novel human cytomegalovirus NK cell evasion functions target MICA for lysosomal degradation. Plos. Pathog. 2014, 10:e1004058.
24. Goldberger T., Mandelboim O. The use of microRNA by human viruses: lessons from NK cells and HCMV infection. Semin. Immunopathol. 2014, 36:659-674.
25. Gonzalez S., Groh V., Spies T. Immunobiology of human NKG2D and its ligands. Curr. Top. Microbiol. Immunol. 2006, 298:121-138.
26. Groh V., Rhinehart R., Randolph-Habecker J., Topp M.S., Riddell S.R., Spies T. Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat. Immunol. 2001, 2:255-260.
27. Guo Y.W., Huang E.S. Characterization of a structurally tricistronic gene of human cytomegalovirus composed of U(s)18, U(s)19, and U(s)20. J. Virol. 1993, 67:2043-2054.
28. Hegde N.R., Chevalier M.S., Wisner T.W., Denton M.C., Shire K., Frappier L., Johnson D.C. The role of BiP in endoplasmic reticulum-associated degradation of major histocompatibility complex class I heavy chain induced by cytomegalovirus proteins. J. Biol. Chem. 2006, 281:20910-20919.
29. Hegde N.R., Tomazin R.A., Wisner T.W., Dunn C., Boname J.M., Lewinsohn D.M., Johnson D.C. Inhibition of HLA-DR assembly, transport, and loading by human cytomegalovirus glycoprotein US3: a novel mechanism for evading major histocompatibility complex class II antigen presentation. J. Virol. 2002, 76:10929-10941.
30. Huber M.T., Tomazin R., Wisner T., Boname J., Johnson D.C. Human cytomegalovirus US7, US8, US9, and US10 are cytoplasmic glycoproteins, not found at cell surfaces, and US9 does not mediate cell-to-cell spread. J. Virol. 2002, 76:5748-5758.
31. Jamieson A.M., Diefenbach A., McMahon C.W., Xiong N., Carlyle J.R., Raulet D.H. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 2002, 17:19-29.
32. Jones T.R., Muzithras V.P. A cluster of dispensable genes within the human cytomegalovirus genome short component: IRS1, US1 through US5, and the US6 family. J. Virol. 1992, 66:2541-2546.
33. Jung H., Hsiung B., Pestal K., Procyk E., Raulet D.H. RAE-1 ligands for the NKG2D receptor are regulated by E2F transcription factors, which control cell cycle entry. J. Exp. Med. 2012, 209:2409-2422.
34. Kaiser B.K., Yim D., Chow I.T., Gonzalez S., Dai Z., Mann H.H., Strong R.K., Groh V., Spies T. Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature 2007, 447:482-486.
35. Kaye J., Browne H., Stoffel M., Minson T. The UL16 gene of human cytomegalovirus encodes a glycoprotein that is dispensable for growth in vitro. J. Virol. 1992, 66:6609-6615.
36. Klumkrathok K., Jumnainsong A., Leelayuwat C. Allelic MHC class I chain related B (MICB) molecules affect the binding to the human cytomegalovirus (HCMV) unique long 16 (UL16) protein: implications for immune surveillance. J. Microbiol. 2013, 51:241-246.
37. Kollert-Jons A., Bogner E., Radsak K. A 15-kilobase-pair region of the human cytomegalovirus genome which includes US1 through US13 is dispensable for growth in cell culture. J. Virol. 1991, 65:5184-5189.
38. Kubin M., Cassiano L., Chalupny J., Chin W., Cosman D., Fanslow W., Mullberg J., Rousseau A.M., Ulrich D., Armitage R. ULBP1, 2, 3: novel MHC class I-related molecules that bind to human cytomegalovirus glycoprotein UL16, activate NK cells. Eur. J. Immunol. 2001, 31:1428-1437.
39. Lesniewski M., Das S., Skomorovska-Prokvolit Y., Wang F.Z., Pellett P.E. Primate cytomegalovirus US12 gene family: a distinct and diverse clade of seven-transmembrane proteins. Virology 2006, 354:286-298.
40. Liu C., Qi Y., Ma Y., He R., Sun Z., Huang Y., Ji Y., Ruan Q. Interaction between the human cytomegalovirusencoded UL142 and cellular Snapin proteins. Mol. Med. Rep. 2015, 11:1069-1072.
41. Liu G., Atteridge C.L., Wang X., Lundgren A.D., Wu J.D. The membrane type matrix metalloproteinase MMP14 mediates constitutive shedding of MHC class I chain-related molecule A independent of A disintegrin and metalloproteinases. J. Immunol. 2010, 184:3346-3350.
42. Long E.O., Kim H.S., Liu D., Peterson M.E., Rajagopalan S. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu. Rev. Immunol. 2013, 31:227-258.
43. Maidji E., Tugizov S., Abenes G., Jones T., Pereira L. A novel human cytomegalovirus glycoprotein, gpUS9, which promotes cell-to-cell spread in polarized epithelial cells, colocalizes with the cytoskeletal proteins E-cadherin and F-actin. J. Virol. 1998, 72:5717-5727.
44. Maidji E., Tugizov S., Jones T., Zheng Z., Pereira L. Accessory human cytomegalovirus glycoprotein US9 in the unique short component of the viral genome promotes cell-to-cell transmission of virus in polarized epithelial cells. J. Virol. 1996, 70:8402-8410.
45. Mandic L., Miller M.S., Coulter C., Munshaw B., Hertel L. Human cytomegalovirus US9 protein contains an N-terminal signal sequence and a C-terminal mitochondrial localization domain, and does not alter cellular sensitivity to apoptosis. J. Gen. Virol. 2009, 90:1172-1182.
46. McFarland B.J., Strong R.K. Thermodynamic analysis of degenerate recognition by the NKG2D immunoreceptor: not induced fit but rigid adaptation. Immunity 2003, 19:803-812.
47. McGeoch D.J., Cook S., Dolan A., Jamieson F.E., Telford E.A. Molecular phylogeny and evolutionary timescale for the family of mammalian herpesviruses. J. Mol. Biol. 1995, 247:443-458.
48. Mocarski E.S., Shenk T., Griffiths P.D., Pass R.F. Cytomegaloviruses 2013, Lippincott Williams and Wilkins, Philadelphia.
49. Muller S., Zocher G., Steinle A., Stehle T. Structure of the HCMV UL16-MICB complex elucidates select binding of a viral immunoevasin to diverse NKG2D ligands. Plos. Pathog. 2010, 6:e1000723.
50. Novotny J., Rigoutsos I., Coleman D., Shenk T. In silico structural and functional analysis of the human cytomegalovirus (HHV5) genome. J. Mol. Biol. 2001, 310:1151-1166.
51. Ota M., Katsuyama Y., Mizuki N., Ando H., Furihata K., Ono S., Pivetti-Pezzi P., Tabbara K.F., Palimeris G.D., Nikbin B., Davatchi F., Chams H., Geng Z., Bahram S., Inoko H. Trinucleotide repeat polymorphism within exon 5 of the MICA gene (MHC class I chain-related gene A): allele frequency data in the nine population groups Japanese, Northern Han, Hui, Uygur, Kazakhstan, Iranian, Saudi Arabian, Greek and Italian. Tissue Antigens 1997, 49:448-454.
52. Pereira L., Maidji E., Tugizov S., Jones T. Deletion mutants in human cytomegalovirus glycoprotein US9 are impaired in cell-cell transmission and in altering tight junctions of polarized human retinal pigment epithelial cells. Scand. J. Infect. Dis. Suppl. 1995, 99:82-87.
53. Radosavljevic M., Cuillerier B., Wilson M.J., Clement O., Wicker S., Gilfillan S., Beck S., Trowsdale J., Bahram S. A cluster of ten novel MHC class I related genes on human chromosome 6q24.2-q25.3. Genomics 2002, 79:114-123.
54. Raulet D.H., Gasser S., Gowen B.G., Deng W., Jung H. Regulation of ligands for the NKG2D activating receptor. Annu. Rev. Immunol. 2013, 31:413-441.
55. Revilleza M.J., Wang R., Mans J., Hong M., Natarajan K., Margulies D.H. How the virus outsmarts the host: function and structure of cytomegalovirus MHC-I-like molecules in the evasion of natural killer cell surveillance. J. Biomed. Biotechnol. 2011, 2011:724607.
56. Rolle A., Mousavi-Jazi M., Eriksson M., Odeberg J., Soderberg-Naucler C., Cosman D., Karre K., Cerboni C. Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein. J. Immunol. 2003, 171:902-908.
57. Saez-Borderias A., Guma M., Angulo A., Bellosillo B., Pende D., Lopez-Botet M. Expression and function of NKG2D in CD4+ T cells specific for human cytomegalovirus. Eur. J. Immunol. 2006, 36:3198-3206.
58. Schrambach S., Ardizzone M., Leymarie V., Sibilia J., Bahram S. In vivo expression pattern of MICA and MICB and its relevance to auto-immunity and cancer. Plos. One 2007, 2:e518.
59. Seidel E., Le V.T., Bar-On Y., Tsukerman P., Enk J., Yamin R., Stein N., Schmiedel D., Oiknine Djian E., Weisblum Y., Tirosh B., Stastny P., Wolf D.G., Hengel H., Mandelboim O. Dynamic Co-evolution of Host and Pathogen: HCMV Downregulates the Prevalent Allele MICA *008 to Escape Elimination by NK Cells. Cell. Rep. 2015.
60. Sijmons S., Thys K., Mbong Ngwese M., Van Damme E., Dvorak J., Van Loock M., Li G., Tachezy R., Busson L., Aerssens J., Van Ranst M., Maes P. High-throughput analysis of human cytomegalovirus genome diversity highlights the widespread occurrence of gene-disrupting mutations and pervasive recombination. J. Virol. 2015.
61. Snyder M.R., Weyand C.M., Goronzy J.J. The double life of NK receptors: stimulation or co-stimulation?. Trends Immunol. 2004, 25:25-32.
62. Spreu J., Stehle T., Steinle A. Human cytomegalovirus-encoded UL16 discriminates MIC molecules by their alpha2 domains. J. Immunol. 2006, 177:3143-3149.
63. Stark T.J., Arnold J.D., Spector D.H., Yeo G.W. High-resolution profiling and analysis of viral and host small RNAs during human cytomegalovirus infection. J. Virol. 2012, 86:226-235.
64. Sutherland C.L., Chalupny N.J., Cosman D. The UL16-binding proteins, a novel family of MHC class I-related ligands for NKG2D, activate natural killer cell functions. Immunol. Rev. 2001, 181:185-192.
65. Upshaw J.L., Arneson L.N., Schoon R.A., Dick C.J., Billadeau D.D., Leibson P.J. NKG2D-mediated signaling requires a DAP10-bound Grb2-Vav1 intermediate and phosphatidylinositol-3-kinase in human natural killer cells. Nat. Immunol. 2006, 7:524-532.
66. Vales-Gomez M. The Impact of Glycosyl-Phosphatidyl-Inositol Anchored MICA Alleles on Novel NKG2D-Based Therapies. Front. Immunol. 2015, 6:193.
67. Vales-Gomez M., Browne H., Reyburn H.T. Expression of the UL16 glycoprotein of Human Cytomegalovirus protects the virus-infected cell from attack by natural killer cells. BMC Immunol. 2003, 4:4.
68. Vales-Gomez M., Chisholm S.E., Cassady-Cain R.L., Roda-Navarro P., Reyburn H.T. Selective induction of expression of a ligand for the NKG2D receptor by proteasome inhibitors. Cancer Res. 2008, 68:1546-1554.
69. Vales-Gomez M., Reyburn H.T. Intracellular trafficking of the HCMV immunoevasin UL16 depends on elements present in both its cytoplasmic and transmembrane domains. J. Mol. Biol. 2006, 363:908-917.
70. Vales-Gomez M., Shiroishi M., Maenaka K., Reyburn H.T. Genetic variability of the major histocompatibility complex class I homologue encoded by human cytomegalovirus leads to differential binding to the inhibitory receptor ILT2. J. Virol. 2005, 79:2251-2260.
71. Vales-Gomez M., Winterhalter A., Roda-Navarro P., Zimmermann A., Boyle L., Hengel H., Brooks A., Reyburn H.T. The human cytomegalovirus glycoprotein UL16 traffics through the plasma membrane and the nuclear envelope. Cell. Microbiol. 2006, 8:581-590.
72. Venkataraman G.M., Suciu D., Groh V., Boss J.M., Spies T. Promoter region architecture and transcriptional regulation of the genes for the MHC class I-related chain A and B ligands of NKG2D. J. Immunol. 2007, 178:961-969.
73. Verneris M.R., Karimi M., Baker J., Jayaswal A., Negrin R.S. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood 2004, 103:3065-3072.
74. Waldhauer I., Goehlsdorf D., Gieseke F., Weinschenk T., Wittenbrink M., Ludwig A., Stevanovic S., Rammensee H.G., Steinle A. Tumor-associated MICA is shed by ADAM proteases. Cancer Res. 2008, 68:6368-6376.
75. Wang F.Z., Weber F., Croce C., Liu C.G., Liao X., Pellett P.E. Human cytomegalovirus infection alters the expression of cellular microRNA species that affect its replication. J. Virol. 2008, 82:9065-9074.
76. Weekes M.P., Tomasec P., Huttlin E.L., Fielding C.A., Nusinow D., Stanton R.J., Wang E.C., Aicheler R., Murrell I., Wilkinson G.W., Lehner P.J., Gygi S.P. Quantitative temporal viromics: an approach to investigate host-pathogen interaction. Cell 2014, 157:1460-1472.
77. Welte S.A., Sinzger C., Lutz S.Z., Singh-Jasuja H., Sampaio K.L., Eknigk U., Rammensee H.G., Steinle A. Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein. Eur. J. Immunol. 2003, 33:194-203.
78. Weston K., Barrell B.G. Sequence of the short unique region, short repeats, and part of the long repeats of human cytomegalovirus. J. Mol. Biol. 1986, 192:177-208.
79. Wilkinson G.W., Tomasec P., Stanton R.J., Armstrong M., Prod'homme V., Aicheler R., McSharry B.P., Rickards C.R., Cochrane D., Llewellyn-Lacey S., Wang E.C., Griffin C.A., Davison A.J. Modulation of natural killer cells by human cytomegalovirus. J. Clin. Virol.: Off. Publ. Pan Am. Soc. Clin. Virol. 2008, 41:206-212.
80. Wills M.R., Ashiru O., Reeves M.B., Okecha G., Trowsdale J., Tomasec P., Wilkinson G.W., Sinclair J., Sissons J.G. Human cytomegalovirus encodes an MHC class I-like molecule (UL142) that functions to inhibit NK cell lysis. J. Immunol. 2005, 175:7457-7465.
81. Wu J., Chalupny N.J., Manley T.J., Riddell S.R., Cosman D., Spies T. Intracellular retention of the MHC class I-related chain B ligand of NKG2D by the human cytomegalovirus UL16 glycoprotein. J. Immunol. 2003, 170:4196-4200.
82. Wu J., Song Y., Bakker A.B., Bauer S., Spies T., Lanier L.L., Phillips J.H. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 1999, 285:730-732.
83. Yang X., Du W.W., Li H., Liu F., Khorshidi A., Rutnam Z.J., Yang B.B. Both mature miR-17-5p and passenger strand miR-17-3p target TIMP3 and induce prostate tumor growth and invasion. Nucleic Acids Res. 2013, 41:9688-9704.
84. Yu D., Silva M.C., Shenk T. Functional map of human cytomegalovirus AD169 defined by global mutational analysis. Proc. Natl. Acad. Sci. USA 2003, 100:12396-12401.
85. Zou Y., Bresnahan W., Taylor R.T., Stastny P. Effect of human cytomegalovirus on expression of MHC class I-related chains A. J. Immunol. 2005, 174:3098-3104.